全文获取类型
收费全文 | 7970篇 |
免费 | 423篇 |
国内免费 | 51篇 |
专业分类
耳鼻咽喉 | 145篇 |
儿科学 | 113篇 |
妇产科学 | 73篇 |
基础医学 | 848篇 |
口腔科学 | 127篇 |
临床医学 | 665篇 |
内科学 | 2206篇 |
皮肤病学 | 114篇 |
神经病学 | 575篇 |
特种医学 | 317篇 |
外科学 | 1445篇 |
综合类 | 25篇 |
一般理论 | 1篇 |
预防医学 | 274篇 |
眼科学 | 165篇 |
药学 | 406篇 |
中国医学 | 13篇 |
肿瘤学 | 932篇 |
出版年
2023年 | 77篇 |
2022年 | 124篇 |
2021年 | 282篇 |
2020年 | 137篇 |
2019年 | 188篇 |
2018年 | 209篇 |
2017年 | 146篇 |
2016年 | 182篇 |
2015年 | 190篇 |
2014年 | 262篇 |
2013年 | 290篇 |
2012年 | 482篇 |
2011年 | 572篇 |
2010年 | 310篇 |
2009年 | 232篇 |
2008年 | 427篇 |
2007年 | 513篇 |
2006年 | 489篇 |
2005年 | 567篇 |
2004年 | 534篇 |
2003年 | 500篇 |
2002年 | 442篇 |
2001年 | 81篇 |
2000年 | 100篇 |
1999年 | 91篇 |
1998年 | 88篇 |
1997年 | 54篇 |
1996年 | 82篇 |
1995年 | 50篇 |
1994年 | 43篇 |
1993年 | 36篇 |
1992年 | 55篇 |
1991年 | 66篇 |
1990年 | 35篇 |
1989年 | 69篇 |
1988年 | 52篇 |
1987年 | 53篇 |
1986年 | 40篇 |
1985年 | 50篇 |
1984年 | 23篇 |
1983年 | 18篇 |
1982年 | 14篇 |
1981年 | 12篇 |
1980年 | 12篇 |
1979年 | 22篇 |
1977年 | 10篇 |
1971年 | 10篇 |
1970年 | 10篇 |
1968年 | 16篇 |
1967年 | 16篇 |
排序方式: 共有8444条查询结果,搜索用时 15 毫秒
991.
Igata M Motoshima H Tsuruzoe K Kojima K Matsumura T Kondo T Taguchi T Nakamaru K Yano M Kukidome D Matsumoto K Toyonaga T Asano T Nishikawa T Araki E 《Circulation research》2005,97(8):837-844
Vascular smooth muscle cell (VSMC) proliferation is a critical event in the development and progression of vascular diseases, including atherosclerosis. We investigated whether the activation of adenosine monophosphate-activated protein kinase (AMPK) could suppress VSMC proliferation and inhibit cell cycle progression. Treatment of human aortic smooth muscle cells (HASMCs) or isolated rabbit aortas with the AMPK activator 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) induced phosphorylation of AMPK and acetyl Co-A carboxylase. AICAR significantly inhibited HASMC proliferation induced by both platelet-derived growth factor-BB (PDGF-BB) and fetal calf serum (FCS). Treatment with AICAR inhibited the phosphorylation of retinoblastoma gene product (Rb) induced by PDGF-BB or FCS, and increased the expression of cyclin-dependent kinase inhibitor p21(CIP) but not that of p27(KIP). Pharmacological inhibition of AMPK or overexpression of dominant negative-AMPK inhibited both the suppressive effect of AICAR on cell proliferation and the phosphorylation of Rb, suggesting that the effect of AICAR is mediated through the activation of AMPK. Cell cycle analysis in HASMCs showed that AICAR significantly increased cell population in G0/G1-phase and reduced that in S- and G2/M-phase, suggesting AICAR induced cell cycle arrest. AICAR increased both p53 protein and Ser-15 phosphorylated p53 in HASMCs, which were blocked by inhibition of AMPK. In isolated rabbit aortas, AICAR also increased Ser-15 phosphorylation and protein expression of p53 and inhibited Rb phosphorylation induced by FCS. These data suggest for the first time that AMPK suppresses VSMC proliferation via cell cycle regulation by p53 upregulation. Therefore, AMPK activation in VSMCs may be a therapoietic target for the prevention of vascular diseases. 相似文献
992.
Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis 总被引:5,自引:0,他引:5
Y Matsuzaki N Tanaka T Osuga T Aikawa J Shoda M Doi M Nakano 《The American journal of gastroenterology》1990,85(1):15-23
Ursodeoxycholic acid (UDCA) was administered to 10 patients diagnosed as having primary biliary cirrhosis (PBC) after liver biopsy. Eight patients were anicteric, and two were icteric cases. One patient was in stage I, seven were in stage II, one in stage I-III, and one in stage III-IV of Scheuer's classification. Six hundred milligrams of UDCA were administered orally after meals three times daily to all of the patients for more than 1 yr. The period of UDCA administration ranged from 6 to 41 months. The major findings are as follows: 1) in six out of seven patients with pruritus, itching disappeared 1 month after administration of UDCA; 2) both serum alkaline phosphatase and gamma-glutamyltranspeptidase levels began decreasing significantly the first month after the onset of UDCA treatment, and continued decreasing throughout the treatment; 3) GOT and GPT levels also decreased significantly during the administration of UDCA, compared with before-treatment levels; 4) in one icteric patient with portal hypertension, although serum biliary enzyme levels improved after treatment, serum bilirubin level got worse, and the patient died of esophageal variceal hemorrhage. In another icteric case, biliary and bilirubin levels improved slightly after treatment; 5) antimitochondrial antibody titer decreased in four cases, but IgM levels and other immunological parameters were not changed; 6) serum UDCA increased significantly during UDCA treatment; in particular, glyco-UDCA occupied up to 40% of the total bile acid and CDC decreased to 25%; 7) portal inflammation activity decreased in all five patients who had undergone follow-up liver biopsy, more than 1 yr after UDCA administration--bridging fibrosis decreased in three cases; and 8) no side effects were observed in any of the cases. Although large-scale, randomized, controlled, double-blind tests are necessary, it is speculated that the long-term administration of UDCA is a safe and effective treatment for the improvement of biliary enzyme levels and pruritus in anicteric PBC. 相似文献
993.
Ultrastructural study of the effects of chloroquine and verapamil on Plasmodium falciparum 总被引:2,自引:0,他引:2
G H Jacobs A M Oduola D E Kyle W K Milhous S K Martin M Aikawa 《The American journal of tropical medicine and hygiene》1988,39(1):15-20
Verapamil, a calcium antagonist, has recently been shown to reverse chloroquine resistance in malarial parasites in vitro. We report the first ultrastructural morphological changes associated with this phenomenon using chloroquine-sensitive and -resistant clones of Plasmodium falciparum. While the administration of 6.3 x 10(-8) M chloroquine had little morphological effect on the chloroquine-resistant strain, the combination of chloroquine and verapamil resulted in typical chloroquine-related food vacuolar swelling with increased amounts of granular matrix. Secondary morphological changes included degeneration of nuclei, mitochondria, and other organelles. These effects appeared similar to those in the chloroquine-sensitive strain of P. falciparum treated with chloroquine alone or with the chloroquine/verapamil combination. Furthermore mild food vacuolar changes were seen in a small number of parasites (from both chloroquine-sensitive and -resistant groups) exposed to high concentrations (1 x 10(-4) M) of verapamil alone. 相似文献
994.
Shigeru Nakai Ikuto Masakane Takashi Akiba Takashi Shigematsu Kunihiro Yamagata Yuzo Watanabe Kunitoshi Iseki Noritomo Itami Toshio Shinoda Kunio Morozumi Tetsuo Shoji Seiji Marubayashi Osamu Morita Naoki Kimata Tatsuya Shoji Kazuyuki Suzuki Kenji Tsuchida Hidetomo Nakamoto Takayuki Hamano Akihiro Yamashita Kenji Wakai Atsushi Wada Yoshiharu Tsubakihara 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2008,12(6):428-456
A statistical survey of dialysis patients for the year 2006 was carried out for 4051 medical facilities across Japan, and responses were received from 3985 (98.37%) facilities. There were 264 473 dialysis patients (including 9003 peritoneal dialysis patients) in Japan at the end of 2006, which showed an increase of 6708 (2.6%) from the end of 2005. The number of patients per million population was 2069.9. The crude mortality rate during 2006 was 9.2%. The mean age of the patients who began dialysis (in 2006) was 66.4 years, and the mean age of the entire dialysis population was 64.4 years. The primary renal diseases of the patients who began dialysis were diabetic nephropathy (42.9%), chronic glomerulonephritis (25.6%), and nephrosclerosis (9.4%). Of the 3488 facilities that participated in the survey on the dialysate water quality, 2873 facilities (82.4%) measured the endotoxin concentration in the dialysate; and 1197 facilities (37.1%) out of 3228 measured the bacterial count in the dialysate. The mean hemoglobin concentration in the dialysis population at the end of 2006 was 10.23 ± 1.33 g/dL, which was equal to that at the end of 2005 (10.23 ± 1.37 g/dL). The mean concentration of serum creatinine in 15 853 patients who started dialysis during 2006 was 8.37 ± 3.58 mg/dL. The estimated glomerular filtration rate, which was calculated with formula modified for the Japanese population from the Modification of Diet in Renal Disease (MDRD) Study equation, was 5.46 ± 6.60 mL/min/1.73 m2. 相似文献
995.
PURPOSE: Pyrazinamide is an antituberculous drug that is administered as a two-month course during treatment of pulmonary tuberculosis. Adverse reactions to pyrazinamide have been reported to include hyperuricemia. We performed a retrospective multicenter epidemiological survey to assess the relationship between various patient characteristics and the uric acid level, the changes of uric acid during pyrazinamide administration, and the use of medications for uric acid control as well as attacks of gout or arthralgia at the onset of hyperuricemia. A total of 226 patients who were admitted to four hospitals with pulmonary tuberculosis between January and December 2006 and received short-term intensive pyrazinamide therapy were studied. RESULTS: There were 172 men and 54 women with an average age of 59.5 years and an average body mass index of 19.8 kg/m2. The average serum uric acid concentration before pyrazinamide treatment was 4.73 +/- 1.78 mg/dl, while the average uric acid level after pyrazinamide treatment was 10.63 +/- 2.67 mg/dl, which was significantly higher than the pretreatment level (p<0.0001). During treatment, hyperuricemia (Serum uric acid > or = 8 mg/dl) was reported in 84.5% of patients and arthralgia developed in 4.42%. Although the therapy instituted in 51 patients (22.57%) had to be interrupted or discontinued due to liver dysfunction and skin rashes, which were probably caused by isoniazid and rifampicin, no patient ceased taking pyrazinamide due to an increase of uric acid. Drugs for uric acid control were administered to 21 patients (9.29%). Pyrazinamide is an important agent for intensive short-term antituberculous therapy. Hyperuricemia due to this drug can be managed by observation and does not require interruption of administration. 相似文献
996.
砷与5-氮胞苷对人淋巴细胞DNA损伤的联合作用 总被引:3,自引:0,他引:3
为探讨砷和5-氮胞苷对人淋巴细胞DNA损伤及修复的联合作用,应用单细胞凝胶电泳(SCGE)技术比较研究了5-氮胞苷与砷同时和前后作用于人类淋巴细胞产生的联合毒性,结果显示10μmol/L5-氮胞苷和10μmol/L砷单独处理人淋巴细胞2h引起明显的DNA泳动(彗星尾),但两试剂引起的DNA泳动(彗星尾)间无显差异,5-氮胞苷前处理与砷后处理2h引起的彗星尾与其单独处理组比较非常显,砷前处理与5-氮胞苷后处理引起的彗星尾与其单独处理组比较无显性差异,但较对照组差异显,10μmol/L5-氮胞苷和10μmol/L砷分别单独处理2h引起了人淋巴细胞显的DNA损伤(链断裂),5-氮胞苷与砷在对淋巴细胞DNA的损伤上表现为单纯相加作用。5-氮胞苷前处理显增加了细胞对砷的基因毒性的敏感性,或砷后处理显增加了5-氮胞苷引起的DNA损伤,5-氮胞苷后处理2h显抑制了细胞对砷所致DNA损伤的修复。 相似文献
997.
M Aikawa J Rabbege S Uni M Ristic L H Miller 《The American journal of tropical medicine and hygiene》1985,34(1):45-49
Babesia bovis, causative agent of cattle babesiosis, induces characteristic alterations on the membrane of infected erythrocytes. Elliptical protrusions measuring about 320 nm in long axis and about 160 nm in short axis appear on the membrane of infected erythrocytes, both in vitro and in vivo. Freeze-fracture demonstrated alignment of intramembrane particles (IMP) along the long axis of both the P and E faces of the protrusions. The number of IMP on the endoplasmic face increases, but the number of IMP on the protoplasmic face of the protrusions is not statistically altered from that of uninfected erythrocytes. In vitro, there are more protrusions per erythrocyte infected with the virulent form (low passage form) of B. bovis than with the avirulent form (high passage form). This suggests that the number of protrusions which appear on the membrane of infected erythrocytes may have a direct relationship to the virulence of the parasites. These protrusions may be attached to the capillary endothelial cells, which causes fatal cerebral babesiosis. 相似文献
998.
Evolution of and obstacles in surgical treatment for hepatocellular carcinoma over the last 25 years: differences over four treatment eras 总被引:3,自引:0,他引:3
Yamanaka N Takata M Tanaka T Yamanaka J Yasui C Ando T Kuroda N Maeda S Okamoto E 《Journal of gastroenterology》2000,35(8):613-621
This study was designed to clarify what differences the last 25 years have made in surgical results for patients with hepatocellular
carcinoma (HCC). We examined results for 716 hepatectomized patients in four treatment eras: first era (1973–1980; n = 58), second era (1981–1985; n = 155), third era (1986–1990; n = 243), and fourth era (1991–1997; n = 260). Patient background, tumor characteristics, type of hepatectomy, treatment for intrahepatic recurrences, and surgical
results in the four eras were compared by univariate analysis to clarify the factors that have contributed to or impeded progress
in the surgical treatment of HCC. Although there were no significant chronological differences in liver pathology and surgical
resectability, operative mortality was reduced to 2% in the fourth era, from 29% in the first era. With an increasing proportion
of early-stage HCCs (TNM, stages I and II), the cumulative survival rate at 5 years improved in the course of the eras in
our overall population of patients (12%, 31%, 38%, and 51%, respectively, for the first, second, third, and fourth eras) and
in a subset of the population divided according to tumor stage. Also, we found a chronological improvement in the survival
rate at 3 years after intrahepatic recurrence (10%, 28%, 36%, and 44%, respectively in the first second, third, and fourth
eras). This improvement was associated with the establishment of an early detection program for intrahepatic recurrences.
However, the recurrence rate was similar in any subset of the population through the four eras. Although this univariate study
could not determine independent factors that contributed to the chronological progress in results for HCC surgery in the four
eras, it is conceivable that the establishment of indication criteria for hepatectomy, an early detection program for primary
and recurrent lesions, and the introduction of multimodal treatment for recurrence were contributory factors in this im-provement.
A strategy for alleviating the frequent recurrences originating from posthepatectomy metachronous carcinogenesis remains to
be established.
Received: September 28, 1999 / Accepted: February 25, 2000 相似文献
999.
1000.
Yasuda S Atsumi T Matsuura E Kaihara K Yamamoto D Ichikawa K Koike T 《Arthritis and rheumatism》2005,52(1):212-218
OBJECTIVE: To clarify the consequences of the valine/leucine polymorphism at position 247 of the beta(2)-glycoprotein I (beta(2)GPI) gene in patients with antiphospholipid syndrome (APS), by investigating the correlation between genotypes and the presence of anti-beta(2)GPI antibody. The reactivity of anti-beta(2)GPI antibodies was characterized using recombinant Val(247) and Leu(247) beta(2)GPI. METHODS: Sixty-five Japanese patients with APS and/or systemic lupus erythematosus who were positive for antiphospholipid antibodies and 61 controls were analyzed for the presence of the Val/Leu(247) polymorphism of beta(2)GPI. Polymorphism assignment was determined by polymerase chain reaction followed by restriction enzyme digestion. Recombinant Val(247) and Leu(247) beta(2)GPI were established to compare the reactivity of anti-beta(2)GPI antibodies to beta(2)GPI between these variants. The variants were prepared on polyoxygenated plates or cardiolipin-coated plates, and the reactivity of a series of anti-beta(2)GPI antibodies (immunized anti-human beta(2)GPI monoclonal antibodies [Cof-19-21] and autoimmune anti-beta(2)GPI monoclonal antibodies [EY1C8, EY2C9, and TM1G2]) and IgGs purified from patient sera was investigated. RESULTS: A positive correlation between the Val(247) allele and the presence of anti-beta(2)GPI antibodies was observed in the patient group. Human monoclonal/polyclonal anti-beta(2)GPI autoantibodies showed higher binding to recombinant Val(247) beta(2)GPI than to Leu(247) beta(2)GPI, although no difference in the reactivity of the immunized anti-beta(2)GPI between these variants was observed. Conformational optimization showed that the replacement of Leu(247) by Val(247) led to a significant alteration in the tertiary structure of domain V and/or the domain IV-V interaction. CONCLUSION: The Val(247) beta(2)GPI allele was associated with both a high frequency of anti-beta(2)GPI antibodies and stronger reactivity with anti-beta(2)GPI antibodies compared with the Leu(247) beta(2)GPI allele, suggesting that the Val(247) beta(2)GPI allele may be one of the genetic risk factors for development of APS. 相似文献